The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
 
Luis G. Paz-Ares
Leadership - ALTUM Sequencing; Genomica
Honoraria - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Ipsen; Lilly; Merck Serono; Mirati Therapeutics; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Takeda
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I)
 
Tudor-Eliade Ciuleanu
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Ipsen; Janssen; MSD; Pfizer; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Amgen; Astellas Amgen BioPharama; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Ipsen; Janssen; MSD; Pfizer; Roche; Sanofi; SERVIER
 
Jong-Seok Lee
Consulting or Advisory Role - AstraZeneca; Ono Pharmaceutical
 
Laszlo Urban
Travel, Accommodations, Expenses - Roche
 
Reyes Bernabe Caro
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Roche; Takeda
 
Keunchil Park
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; JNJ; Lilly; LOXO; Merck KGaA; MSD; Ono Pharmaceutical; Puma Biotechnology
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca; MSD Oncology
 
Hiroshi Sakai
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck KGaA; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yuichiro Ohe
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Celltrion; Chugai Pharma; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Celltrion; Chugai Pharma; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Ignyta (Inst); Janssen (Inst); Kissei Pharmaceutical (Inst); Kyorin (Inst); Lilly Japan (Inst); LOXO (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Makoto Nishio
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Teijin Pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Adam Pluzanski
Speakers' Bureau - Bristol-Myers Squibb
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Suresh S. Ramalingam
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Genentech/Roche; GlaxoSmithKline; Lilly/ImClone; Merck; Mirati Therapeutics; Takeda
Research Funding - Abbvie (Inst); Advaxis (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Julie R. Brahmer
Honoraria - Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Lilly; Merck; Regeneron; Sanofi
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); RAPT Therapeutics (Inst); Revolution (Inst); Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Janssen Oncology; merck
 
Hossein Borghaei
Stock and Other Ownership Interests - Rgenix; Sonnet
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Celgene; Pfizer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Celgene; EMD Serono; Genentech; Genmab; HUYA Bioscience International; Lilly; Merck; Novartis; Pfizer; PharmaMar; Regeneron; Rgenix; Sonnet; Takeda; Trovagene
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Lilly; Merck; Novartis
Other Relationship - Incyte; Takeda; University of Pennsylvania
 
Kenneth John O'Byrne
Leadership - Carp Pharmaceuticals; Carpe Vitae Pharmaceuticals
Stock and Other Ownership Interests - Carp Pharmaceuticals; Carpe Vitae Pharmaceuticals; DGC Diagnostics
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Roche; Yuhan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Roche; Yuhan
Speakers' Bureau - Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; MSD; Roche
Patents, Royalties, Other Intellectual Property - Carp Pharmaceuticals; Carpe Vitae Pharmceuticals
Travel, Accommodations, Expenses - Boehringer Ingelheim; Roche
 
Matthew D. Hellmann
Stock and Other Ownership Interests - Arcus Biosciences; Immunai; Shattuck Labs; Shattuck Labs
Consulting or Advisory Role - Achilles Therapeutics; Arcus Biosciences; AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Natera; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Lilly
 
Arteid Memaj
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Judith Bushong
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Phuong Tran
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Martin Reck
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Samsung Bioepis
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; Mirati Therapeutics; MSD Oncology; Novartis; Pfizer; Roche/Genentech